Tecentriq (atezolizumab) is an immunotherapy medicine used in the treatment of several types of cancer. Unlike traditional chemotherapy, Tecentriq works by helping the immune system recognize and attack cancer cells.
It belongs to a class of cancer treatments known as immune checkpoint inhibitors and specifically targets a protein called PD-L1.
Depending on the type and stage of cancer, Tecentriq may be prescribed alone or combined with chemotherapy, targeted therapy, or other cancer medicines.
Whether Tecentriq is suitable for a particular patient depends on several factors, including the type of cancer, stage of disease, previous treatments, molecular and biomarker test results, overall health, and the approved treatment protocol being followed.
This guide explains how Tecentriq works, the cancers it may be used to treat, treatment schedules, necessary tests, possible side effects, treatment monitoring, and what patients should know before starting atezolizumab.
What Is Tecentriq?
Tecentriq is the brand name for atezolizumab, a monoclonal antibody used as a form of cancer immunotherapy.
Cancer cells can sometimes avoid immune-system attack by using proteins such as PD-L1 to suppress immune activity.
Atezolizumab binds to PD-L1 and blocks its interaction with immune checkpoints including PD-1. This can restore immune activity against cancer cells and allow the body's immune system to participate more effectively in controlling the tumor.
Because of this mechanism, Tecentriq is known as a PD-L1 immune checkpoint inhibitor.
Is Tecentriq Chemotherapy?
No. Tecentriq is immunotherapy, not chemotherapy.
Traditional chemotherapy acts mainly by damaging or interfering with rapidly dividing cells. Immunotherapy works differently: it modifies immune signaling so the immune system can better recognize and attack cancer cells.
However, Tecentriq is sometimes administered together with chemotherapy.
This means a patient's treatment plan may contain both chemotherapy and immunotherapy even though Tecentriq itself is not a chemotherapy drug.
What Is Atezolizumab?
Atezolizumab is the active ingredient in Tecentriq.
Therefore:
Tecentriq = brand name
Atezolizumab = active substance
Patients searching for terms such as atezolizumab treatment, atezolizumab immunotherapy, or atezolizumab for cancer are generally referring to the same active cancer medicine marketed as Tecentriq.
What Cancers Is Tecentriq Used to Treat?
Atezolizumab has been studied and approved in different jurisdictions for several cancers and clinical settings.
Depending on the country, regulatory approval, tumor characteristics, and treatment protocol, Tecentriq may be used in selected patients with cancers including:
Non-small cell lung cancer (NSCLC)
Small cell lung cancer (SCLC)
Hepatocellular carcinoma (HCC)
Urothelial and bladder cancer
Certain forms of melanoma
Alveolar soft part sarcoma (ASPS)
Some jurisdictions have additional or different approved indications.
The exact indication is important because Tecentriq is not automatically appropriate for every patient with one of these cancers.
Cancer subtype, disease stage, previous treatment and biomarkers may determine whether atezolizumab is appropriate.
Tecentriq for Lung Cancer
Lung cancer is one of the major areas in which atezolizumab is used.
However, treatment differs considerably between non-small cell lung cancer and small cell lung cancer.
Tecentriq for Non-Small Cell Lung Cancer (NSCLC)
Tecentriq may be used in selected patients with NSCLC in several treatment settings, depending on tumor stage, previous treatment and biomarker results.
In some patients, it may be used as a single-agent immunotherapy.
In others, atezolizumab may be combined with other systemic cancer treatments.
It may also be used as adjuvant therapy after surgery and platinum-based chemotherapy in appropriately selected patients with early-stage NSCLC at high risk of recurrence.
Testing may include:
PD-L1 expression
EGFR mutation
ALK alterations
Other molecular testing according to the clinical situation
The presence of certain actionable mutations can significantly change the preferred treatment strategy.
Tecentriq for Small Cell Lung Cancer (SCLC)
For extensive-stage small cell lung cancer, atezolizumab can form part of first-line treatment in combination with chemotherapy such as:
Atezolizumab + Carboplatin + Etoposide
After the initial treatment phase, selected patients may continue immunotherapy according to the treatment protocol and response.
Maintenance strategies can also depend on the currently approved regimen and jurisdiction.
Tecentriq for Liver Cancer
Tecentriq is an important immunotherapy option in selected patients with hepatocellular carcinoma (HCC), the most common form of primary liver cancer.
A widely used regimen combines:
Atezolizumab + Bevacizumab
This combination may be considered for selected patients with unresectable or metastatic HCC who have not previously received systemic treatment, according to the applicable treatment protocol.
Before starting treatment, the oncology team evaluates several factors, including:
Liver function
General health and performance status
Tumor burden and spread
Risk of bleeding
Blood pressure
Kidney function
Previous treatments
Because bevacizumab can increase bleeding risk, patients with liver disease may require evaluation for esophageal or gastric varices and other bleeding risks before treatment.
Tecentriq for Bladder Cancer
Atezolizumab has also been investigated and used in urothelial and bladder cancers.
The exact indication depends heavily on the regulatory jurisdiction and clinical setting.
A particularly important recent development involves muscle-invasive bladder cancer (MIBC).
In the United States, atezolizumab received approval in 2026 as adjuvant therapy for certain patients following cystectomy when circulating tumor DNA (ctDNA) testing demonstrates molecular residual disease (MRD) using an authorized companion diagnostic.
This illustrates how modern immunotherapy is increasingly connected to molecular testing rather than being selected solely according to the anatomical location of the cancer.
Tecentriq for Melanoma
Atezolizumab may be used as part of a combination treatment for selected patients with BRAF V600 mutation-positive unresectable or metastatic melanoma.
The treatment strategy can involve other targeted medicines, and molecular testing is therefore essential before deciding whether this approach is appropriate.
Tecentriq for Alveolar Soft Part Sarcoma
Atezolizumab is also used in selected patients with alveolar soft part sarcoma (ASPS), a rare type of soft-tissue sarcoma.
Because ASPS is rare, evaluation at a center experienced in sarcoma and multidisciplinary cancer management can be particularly valuable.
Does Tecentriq Work for Every Cancer Patient?
No.
Immunotherapy has transformed cancer treatment, but not every tumor responds to immune checkpoint inhibitors.
Doctors consider several factors before recommending Tecentriq, including:
Cancer type
Histological subtype
Stage
Previous treatments
PD-L1 status when relevant
Molecular mutations
Other biomarkers
Tumor characteristics
Patient's general condition
Autoimmune diseases
Organ function
Previous organ transplantation
Other medications and medical conditions
For some cancers, molecular testing can be just as important as imaging when determining the treatment strategy.
What Is PD-L1 and Why Does It Matter?
PD-L1 (Programmed Death-Ligand 1) is a protein that can be expressed by cancer cells and other cells within the tumor environment.
When PD-L1 interacts with immune checkpoint pathways, it can suppress the activity of T cells that might otherwise attack the tumor.
Tecentriq blocks PD-L1.
For some cancers and treatment settings, doctors may test the tumor for PD-L1 expression before prescribing immunotherapy.
However, PD-L1 is not a universal yes-or-no test for Tecentriq.
Its importance varies according to:
Cancer type
Disease stage
Treatment line
Combination regimen
Regulatory indication
A low PD-L1 result therefore does not have the same meaning across every cancer.
What Tests Are Needed Before Starting Tecentriq?
The oncology team will normally review the patient's diagnosis, pathology, imaging and medical history before treatment.
Testing may include:
Complete blood count (CBC)
Liver function tests
Kidney function tests
Thyroid function
Blood glucose
Electrolytes
Appropriate hormonal tests
CT, MRI or PET/CT when clinically indicated
Pathology review
PD-L1 testing when relevant
Molecular/genetic tumor testing when relevant
Additional tests depend on the cancer and combination regimen.
For example, a patient being considered for atezolizumab plus bevacizumab for liver cancer may require additional assessment of bleeding risk.
How Is Tecentriq Given?
The original formulation of Tecentriq is administered through an intravenous infusion (IV).
Treatment is usually given in a hospital, oncology center, or specialized infusion facility under medical supervision.
Different approved schedules exist.
Common adult intravenous schedules include:
840 mg every 2 weeks
1,200 mg every 3 weeks
1,680 mg every 4 weeks
The appropriate schedule depends on the indication and treatment regimen.
Patients should not select or modify the dose themselves.
A subcutaneous formulation of atezolizumab is also approved in some markets, allowing appropriate patients to receive treatment by injection under the skin rather than intravenous infusion.
How Long Does Tecentriq Treatment Last?
There is no single treatment duration for every patient.
Treatment may continue:
For a defined period
Until completion of an adjuvant protocol
Until the cancer progresses
Until unacceptable toxicity develops
As long as clinical benefit continues under the applicable protocol
For some indications, treatment may be planned for approximately one year, while metastatic treatment may continue according to response, tolerability and the specific protocol.
The oncology team determines when treatment should continue, pause or stop.
How Do Doctors Know If Tecentriq Is Working?
Treatment response is usually evaluated through a combination of:
Clinical symptoms
Physical examination
CT scans
MRI
PET/CT in selected situations
Laboratory tests
Tumor markers when appropriate
Doctors generally compare follow-up imaging with previous scans to determine whether tumors are shrinking, stable or progressing.
Response assessment with immunotherapy can sometimes be more complex than with conventional chemotherapy because immune-based treatments may produce unusual radiological response patterns.
For this reason, treatment decisions should not be made from a scan report alone without clinical oncology review.
What Are the Side Effects of Tecentriq?
Like all cancer medicines, Tecentriq can cause side effects.
The exact side-effect profile also depends on whether it is being given alone or together with chemotherapy or another medicine.
Possible side effects may include:
Fatigue
Reduced appetite
Nausea
Cough
Shortness of breath
Diarrhea
Constipation
Fever
Rash or itching
Joint or muscle discomfort
However, the most important aspect of Tecentriq safety is the possibility of immune-related adverse events.
Immune-Related Side Effects of Tecentriq
Because atezolizumab activates immune responses against cancer, the immune system can sometimes also attack healthy organs.
These complications can potentially affect almost any organ.
Important immune-related adverse events include:
Pneumonitis
Inflammation of the lungs.
Symptoms can include:
New or worsening cough
Shortness of breath
Chest discomfort
Hepatitis
Inflammation of the liver.
Patients may develop abnormal liver tests and sometimes symptoms such as jaundice, dark urine or abdominal discomfort.
Colitis
Inflammation of the bowel.
Symptoms can include:
Persistent diarrhea
Abdominal pain
Blood or mucus in stool
Endocrine Disorders
Immunotherapy can affect hormone-producing glands.
Possible problems include:
Thyroid dysfunction
Adrenal insufficiency
Hypophysitis
Type 1 diabetes
Symptoms such as unusual fatigue, dizziness, severe headache, excessive thirst or unexplained weight changes should be discussed with the treating team.
Nephritis
Inflammation of the kidneys can cause changes in kidney function.
Severe Skin Reactions
Serious immune-mediated skin reactions are uncommon but possible.
Patients should urgently report extensive rash, blistering, peeling skin, or sores involving the mouth or other mucosal areas.
When Should a Patient Receiving Tecentriq Contact Their Doctor Urgently?
Patients should promptly contact their oncology team for new or worsening symptoms, particularly:
Difficulty breathing
Persistent or severe cough
Severe diarrhea
Blood in stool
Yellow skin or eyes
Severe abdominal pain
Significant weakness
Confusion
Severe or persistent headache
Vision changes
Extensive rash or blistering
Marked changes in urination
Unexplained fever
Immune-related complications can sometimes occur during treatment or after treatment has stopped.
Early recognition is important because some complications may require corticosteroids or other immunosuppressive treatment.
Can Tecentriq Be Used With Chemotherapy?
Yes.
Atezolizumab can be used either alone or as part of combination therapy depending on the cancer.
Examples include combinations involving:
Carboplatin
Etoposide
Bevacizumab
Other chemotherapy or targeted agents depending on the approved indication
The treatment combination should be based on the exact cancer diagnosis and established oncology protocol.
Tecentriq vs Chemotherapy: What Is the Difference?
The principal difference is the mechanism of action.
Chemotherapy directly interferes with cancer-cell growth and division.
Tecentriq immunotherapy blocks PD-L1-mediated immune suppression, allowing immune cells to participate more effectively in attacking the tumor.
Their side effects therefore differ.
Chemotherapy is commonly associated with effects such as suppression of blood-cell production, nausea and hair loss depending on the drug.
Checkpoint immunotherapy is particularly associated with immune-mediated inflammation of normal organs.
A patient receiving both therapies can experience adverse effects from both components.
Tecentriq vs Keytruda
Tecentriq (atezolizumab) and Keytruda (pembrolizumab) are both immune checkpoint inhibitors, but they are not identical or automatically interchangeable.
Tecentriq primarily targets PD-L1, whereas pembrolizumab targets PD-1.
Each medicine has its own:
Approved indications
Biomarker requirements
Combination regimens
Treatment schedules
Clinical evidence
The appropriate drug depends on the exact cancer and treatment setting rather than simply choosing one immunotherapy over another.
Can Tecentriq Cure Cancer?
There is no universal answer.
Some patients can achieve substantial and durable responses to immunotherapy, while others may experience stable disease, temporary benefit or no response.
In early-stage cancer, immunotherapy may sometimes be used as part of treatment intended to reduce recurrence risk.
In advanced or metastatic cancer, the objective may be long-term disease control, prolonging survival and maintaining quality of life.
The expected benefit must therefore be discussed in the context of the patient's exact diagnosis and stage.
Can Cancer Progress During Tecentriq Treatment?
Yes.
Not every cancer responds to atezolizumab, and some cancers eventually develop resistance after an initial response.
If imaging suggests progression, the oncology team considers:
Symptoms
Scan findings
Rate and pattern of progression
Previous response
Available alternative treatments
Overall clinical condition
A treatment change should generally be based on comprehensive oncology assessment rather than one isolated result.
Who May Not Be Suitable for Tecentriq?
Additional caution may be necessary in patients with certain conditions, including:
Active autoimmune disease
Previous severe immune-related toxicity
Organ transplantation
Significant lung disease
Active infection
Certain liver disorders
Pregnancy
Other medical conditions requiring immune-suppressing treatment
These conditions do not automatically mean that every patient is excluded, but they require individualized specialist assessment.
Tecentriq and Autoimmune Diseases
Because Tecentriq stimulates immune activity, patients with autoimmune disorders require careful evaluation.
Examples include:
Rheumatoid arthritis
Lupus
Inflammatory bowel disease
Multiple sclerosis
Autoimmune thyroid disorders
The oncologist weighs the potential cancer-treatment benefit against the possibility of triggering or worsening autoimmune disease.
Tecentriq During Pregnancy and Breastfeeding
Atezolizumab can potentially harm a developing fetus because of its effects on immune pathways.
Patients who are pregnant, may become pregnant, or are breastfeeding should discuss this with their oncology team before treatment.
Appropriate contraception and breastfeeding recommendations should be followed according to the current product information and treating physician's advice.
What Happens Before Each Tecentriq Session?
Before treatment, the oncology team may review:
Current symptoms
New side effects
Blood counts
Liver function
Kidney function
Thyroid and other endocrine tests when appropriate
Current medications
Performance status
Treatment may sometimes be delayed when significant toxicity or abnormal laboratory results are detected.
Can Tecentriq Be Stopped Temporarily?
Yes.
Doctors may temporarily withhold Tecentriq when significant immune-related or other adverse events develop.
Depending on the type and severity of the reaction, management may involve:
Close observation
Corticosteroids
Hormone replacement
Other immunosuppressive treatment
Temporary treatment interruption
Permanent discontinuation in severe cases
Patients should never restart treatment independently after an interruption.
Preparing for a Tecentriq Oncology Consultation
If you are seeking a second opinion or treatment evaluation for atezolizumab, having complete medical records can make the assessment faster and more accurate.
Useful documents include:
Pathology report
Biopsy results
Pathology slides or blocks when available
Latest CT, MRI or PET/CT
Previous imaging
Molecular profiling results
PD-L1 test results
Previous chemotherapy or immunotherapy protocols
Operative reports
Radiation therapy records
Recent laboratory tests
Current medication list
For international patients, sending these records before traveling may allow the oncology team to perform an initial medical review and determine which additional investigations may be necessary.
Seeking Tecentriq (Atezolizumab) Treatment in Egypt
Patients considering Tecentriq treatment in Egypt should first undergo oncology assessment rather than arranging the medicine independently.
Macrocare can coordinate the patient's case with appropriate oncology specialists and hospitals in Egypt.
The process can include:
Reviewing the patient's medical records.
Identifying the appropriate oncology specialist.
Arranging a medical second opinion.
Confirming whether atezolizumab is clinically appropriate.
Identifying any additional pathology, PD-L1 or molecular testing required.
Coordinating hospital appointments and treatment sessions.
Supporting international patients with treatment planning and medical-trip coordination.
Supporting follow-up and continuity of care.
If the patient has already been prescribed Tecentriq, the prescription, diagnosis, required dose and planned treatment protocol should be reviewed before treatment is arranged.
Frequently Asked Questions About Tecentriq
Is Tecentriq the same as atezolizumab?
Yes. Atezolizumab is the active ingredient marketed under the brand name Tecentriq.
Is Tecentriq chemotherapy?
No. Tecentriq is an immune checkpoint inhibitor used in cancer immunotherapy, although it can be administered together with chemotherapy.
What does Tecentriq treat?
Depending on the clinical setting and regulatory jurisdiction, atezolizumab is used in selected cases of lung cancer, liver cancer, bladder/urothelial cancer, melanoma and alveolar soft part sarcoma, among other specifically approved settings.
Is Tecentriq used for lung cancer?
Yes. Atezolizumab is used in selected patients with both non-small cell and small cell lung cancers.
Is Tecentriq used for liver cancer?
Yes. Atezolizumab combined with bevacizumab is an established treatment option for appropriately selected patients with unresectable or metastatic hepatocellular carcinoma.
Is Tecentriq an immunotherapy drug?
Yes. Tecentriq is a PD-L1 immune checkpoint inhibitor.
How often is Tecentriq given?
For intravenous Tecentriq, commonly used adult schedules include 840 mg every two weeks, 1,200 mg every three weeks or 1,680 mg every four weeks. The exact regimen depends on the indication and treatment protocol.
How many Tecentriq doses will I need?
There is no fixed number for every patient. Treatment duration depends on the cancer, treatment setting, response, toxicity and protocol.
Does Tecentriq cause hair loss?
Hair loss is not typically considered one of the defining adverse effects of Tecentriq monotherapy. However, patients receiving Tecentriq together with chemotherapy may experience hair loss because of the chemotherapy component.
Can Tecentriq cause fatigue?
Yes. Fatigue can occur during atezolizumab treatment. Significant or worsening fatigue should be discussed with the oncology team because it can sometimes also indicate an endocrine or other immune-related complication.
Can Tecentriq cause thyroid problems?
Yes. Immune checkpoint inhibitors can cause thyroid dysfunction and other endocrine disorders. Thyroid function is therefore commonly monitored during treatment.
How do I know whether Tecentriq is working?
Doctors evaluate response using symptoms, examination, imaging and laboratory findings. CT scans are commonly used to monitor tumor response.
What happens if Tecentriq stops working?
The oncology team reassesses the disease and may recommend another systemic treatment, targeted therapy, chemotherapy, radiotherapy, surgery, a clinical trial or supportive treatment depending on the cancer and clinical situation.
Do I need PD-L1 testing before Tecentriq?
Sometimes. PD-L1 testing is important for certain indications but is not required in exactly the same way for every cancer or treatment combination.
Can I receive Tecentriq after chemotherapy?
Yes, in some cancers and treatment settings. In other situations it is given simultaneously with chemotherapy or used in an adjuvant or maintenance strategy.
The correct sequence depends on the diagnosis and treatment protocol.
Can I travel for Tecentriq treatment?
Potentially, yes. However, patients traveling internationally for immunotherapy should have a clear treatment and follow-up plan because immune-related adverse events can occur between treatment sessions and sometimes require urgent assessment.
Medical Second Opinion for Atezolizumab Treatment
A prescription for Tecentriq should be evaluated in the context of the patient's complete cancer diagnosis.
A second oncology opinion can be particularly useful when:
Immunotherapy has recently been recommended.
The patient is unsure whether Tecentriq is appropriate.
The cancer has progressed after previous treatment.
There are several possible systemic therapies.
Molecular or PD-L1 results need interpretation.
The patient wants to explore treatment in another hospital or country.
Treatment has caused significant adverse effects.
Macrocare can coordinate the patient's medical records with an appropriate oncology specialist for review and help organize the next steps in treatment.
Important: This information is intended for patient education and does not replace evaluation by a medical oncologist. Tecentriq is a prescription anticancer medicine and treatment decisions must be individualized according to the patient's diagnosis, biomarkers, medical condition and applicable clinical guidelines.
